GALAFOLD
migalastatsmall moleculepharmacological chaperone of α-galactosidase A
Fabry Disease
Approved
1 program·0 trials·View drug →
DashboardSell24,679$25.71−$634.4KSell18,785$27.19−$510.8KSell17,670$29.11−$514.4K HepatologyCo-Investigator$683.8K6GastroenterologyResearch Grant$537.0K4HepatologyCo-Investigator$533.7K6GastroenterologyCo-Investigator$493.5K7GastroenterologyEquity / Ownership$490.6K6HepatologyEquity / Ownership$461.2K5GastroenterologyResearch Grant$391.0K4GastroenterologyCo-Investigator$254.3K5HepatologyResearch Grant$251.7K6HepatologyEquity / Ownership$227.4K6
FOLDNASDAQ
Amicus Therapeutics
Amicus Therapeutics, Inc. · Princeton, NJ · founded 2002
Amicus Therapeutics, headquartered in Princeton, New Jersey, is a commercial-stage rare-disease biotech focused on lysosomal storage disorders. It markets GALAFOLD (migalastat), an oral pharmacological chaperone that stabilizes a defective enzyme in Fabry disease, and POMBILITI + OPFOLDA, an enzyme replacement therapy combination for late-onset Pompe disease.
- Lead asset
- GALAFOLD · Approved · Fabry Disease
- small molecule · pharmacological chaperone of α-galactosidase A
- Pipeline
- 1 drug · 1 program
- 1 Rare Disease
- Modalities
- small molecule×1
FocusRare Disease
$9.80-1.41%1Y
FOLD · daily close · illustrative · 1 catalyst marked
Conf.+10%
1Y high$10.391Y low$8.51range$1.88(22%)past catalysts
Peers in this space
BMRN$11.2B
BioMarin
Rel.
0.55
Rare Diseasepeptide
1 programmatch: sector
SRPT$2.8B
Sarepta Therapeutics
Rel.
0.47
Rare Diseasegene therapy
1 programmatch: sector
RCKT$720M
Rocket Pharmaceuticals
Rel.
0.24
Rare Diseasegene therapy
1 programmatch: sector
BMY$105.0B
Bristol Myers Squibb
Rel.
0.65
Cardiology - HFpEFsmall molecule
1 programmatch: modality
INCY$14.6B
Incyte
Rel.
0.72
Oncology - Hemesmall molecule
1 programmatch: modality
MDGL$6.8B
Madrigal
Rel.
0.57
NASH / MASHsmall molecule
1 programmatch: modality
Pipeline & catalysts
Pipeline & catalysts
Pipeline by phase1programs
- Preclin0
- Ph10
- Ph20
- Ph30
- Filed0
- Approved1
Past catalyst impact
DateKindEventOutcome+1W+1M+6M
Jun 29, 2025Conf.GALAFOLD — ASH Late-Breaker — Updated SurvivalMixed+9.7%+5.9%+7.4%
Oct 2, 2024AdComGALAFOLD — Advisory Committee — 12–2 Vote in FavorMixed-15.3%+19.8%-27.1%
Dec 7, 2023PDUFAGALAFOLD — PDUFA — CRL IssuedNegative-39.1%-27.3%-40.6%
% change vs ticker close on the announcement date · backtest illustrative
Smart money
Insider activity
Insider activity · last 90 days
Form 4 trail · 3 transactions · 3 insiders
Net flow
−$1.7M
Buys
$0
0 txns
Sells
$1.7M
3 txns
Largest
−$634.4K
EVP sell
Net flow per quarter · last 8Q
4 txns · sum −$2.02M
24Q325Q125Q326Q126Q2
buys · $0sells · $2.02M
Insider · roleActionSharesPriceValueDate
N. Volkov
EVP
Apr 5, 2026
A. Lindberg
CFO
Mar 28, 2026
C. Lindberg
SVP
Feb 25, 2026
Congressional trading
Congressional trading · STOCK Act · last 365d
3 trades · 3 members
Est. net flow
+$75K
midpoint · brackets only
Buys
2
Sells
1
Party mix
2 D1 R
Member · chamberActionBracket~ midpointOwnerDate · disclosure
D
Buy$250K–$500K~$375KspouseRep. L. Marquez
House · NM
Apr 18, 2026
filed +40d
D
Buy$50K–$100K~$75KselfSen. E. Mendoza
Senate · AZ
Apr 16, 2026
filed +18d
R
Sell$250K–$500K~$375KspouseSen. B. Tucker
Senate · TN
Jun 17, 2025
filed +8d
Source: Senate eFD & House Clerk PTR feeds · members must disclose within 45 days · midpoints reflect bracket midpoint, not actual transaction value
Top ETF holders
ETF holders · NAV disclosures
3 ETFs hold the position
Held by ETFs
$12.4M
aggregate position
Of market cap
0.43%
aggregate ETF share
Top holder
XBI0.14%
SPDR S&P Biotech ETF
TickerETF · familyThemeNAV% of NAVPosition
XBIBroad biotech$7.90B0.14%$11.1M
SPDR S&P Biotech ETF
SPDR
BBCSmall-cap biotech$60.0M1.49%$894K
Virtus LifeSci Biotech Clinical Trials
WisdomTree
PBEBroad biotech$175.0M0.24%$420K
Invesco Dynamic Biotechnology
Invesco
Source: ETF NAV disclosures + quarterly 13F filings · narrow-theme ETFs disclose holdings daily; broad ETFs quarterly · % of NAV is the position weight inside the fund
KOL network
KOL network · CMS OpenPayments
18 physicians paid · 84 disclosed records
Total 2025+2024
$5.27M
YoY
+174%
Research Grant$2.22MCo-Investigator$1.50MEquity / Ownership$1.20MConsulting$188.3KSpeaking$89.8KTravel & Lodging$61.9KFood & Beverage$3.0K
Physician · affiliationSpecialtyTop categoryTotalRecords
Dr. Anita Singh
Cedars-Sinai
Dr. Ahmed Singh
Vanderbilt
Dr. Marcus Davies
MD Anderson
Dr. Rebecca Lindberg
University of Michigan
Dr. James Andersson
University of Washington
Dr. Maya Hoffman
University of Michigan
Dr. James Greene
Mayo Clinic
Dr. Liam Walsh
UCSF
Dr. Anita Walsh
Stanford Medicine
Dr. Henry Reyes
Stanford Medicine
Source: CMS OpenPayments · quarterly drops · physicians identified by NPI · aggregated across all programs
Government & IP
Federal lobbying
Federal lobbying · LDA · last 8 quarters
$137K disclosed · 4 firms engaged
YoY change
+41%
last 4Q vs prior 4Q
24Q3Q425Q1Q2Q3Q426Q1Q2
Top lobbying firms · last 8Q
Van Scoyoc Associates$60K
7 quarters active
Akin Gump Strauss Hauer & Feld$29K
5 quarters active
Thorn Run Partners$27K
4 quarters active
Tiber Creek Group$21K
4 quarters active
Top issues lobbied
- Patent Trial and Appeal Board reforms$60K
- CMS Quality Reporting Program$20K
- Inflation Reduction Act drug-price negotiation$14K
- Pharmacy Benefit Manager (PBM) reform$14K
- CMS reimbursement rates for ultra-rare conditions$11K
Source: Senate LDA database (lda.senate.gov) · quarterly registrant filings · spend is the company-wide total disclosed
Government contracts
Federal contracts · USAspending.gov
2 awards · 2 agencies
Total awarded
$19.1M
across all programs
Active
$19.1M
option periods incl.
Top agency
NIH / NIAID$14.3M
largest active: Vaccine Adjuvant Research — Phase 1 / 2
AgencyTitle · type · award IDStatusValueAwarded → ends
NIH / NCIactive$4.8MMay 2025→ Feb 2027
Rare Cancer Translational Research Grant
Grant · NIH-15673828
NIH / NIAIDactive$14.3MMar 2025→ Nov 2027
Vaccine Adjuvant Research — Phase 1 / 2
Grant · NIH-72749945
Source: USAspending.gov · SAM.gov · every federal contract / grant / cooperative agreement is public · values are obligated awards (may include option periods)
U.S. Patents
U.S. Patents · USPTO
4 granted · 2 pending
Total in portfolio
6
Granted in last 12mo
2
Expiring < 2yr
0
Nearest expiry
Apr 2030
Patent #Title · inventor · drugTypeStatus · filedExpiry
12,198,288Composition of Matter
Therapeutic peptide compositions for GALAFOLD
S. Romano + 3 · GALAFOLD
grantedfiled Apr 2024
exp. Apr 2044
18.0y left
US 2026/5919196 A1Process
Purification methods for GALAFOLD
E. Müller + 4 · GALAFOLD
pendingfiled Apr 2026
in prosecution
11,613,815Composition of Matter
Small molecule modulators of GALAFOLD
M. Hoffman + 1 · GALAFOLD
grantedfiled Apr 2021
exp. Apr 2041
15.0y left
US 2024/6365528 A1Composition of Matter
Antibody-drug conjugates with novel linkers for GALAFOLD
N. Hoffman + 1 · GALAFOLD
pendingfiled Apr 2024
in prosecution
12,417,759Composition of Matter
Bispecific antibody compositions targeting GALAFOLD
D. Tanaka + 1 · GALAFOLD
grantedfiled Apr 2013
exp. Apr 2033
7.0y left
11,796,119Method of Use
Pediatric methods of use for GALAFOLD
S. Park + 1 · GALAFOLD
grantedfiled Apr 2010
exp. Apr 2030
4.0y left
Source: USPTO PEDS & Patent Public Search · composition-of-matter is the headline asset · expiration = 20 years from filing
News
News
News · last 90 days
10 items from 5 categories
clinical4earnings2partnership2corporate1regulatory1
1d ago
FOLD reports Q4 results, reaffirms 2026 guidance
Business Wire·earnings
1d ago
FOLD expands manufacturing capacity at lead facility
Business Wire·corporate
2d ago
FOLD doses first patient in Phase 3 GALAFOLD study
Endpoints News$·clinical
4d ago
FOLD expands co-development partnership for next-gen pipeline
PR Newswire·partnership
4d ago
FOLD closes ex-U.S. rights deal worth $2.7 billion in milestones
PR Newswire·partnership
15d ago
FOLD presents GALAFOLD data at major medical conference
FierceBiotech·clinical
2mo ago
FOLD reports topline results from Phase 2 trial of GALAFOLD
Endpoints News$·clinical
2mo ago
FOLD reports Q4 results, reaffirms 2026 guidance
Business Wire·earnings
2mo ago
FOLD presents GALAFOLD data at major medical conference
FierceBiotech·clinical
3mo ago
EMA validates FOLD's Marketing Authorization Application for GALAFOLD
PR Newswire·regulatory
Sources: PR wires + biotech-trade publications + company IR · paywalled outlets ($) link to publisher · we never paraphrase the headline
Financials
Financials
Trading
Previous close
$9.80
Open
$9.84
Day Δ
-0.04
-0.41%
Day range
$9.72 – $9.92
52W range
$8.51 – $10.39
Avg daily volume
2.25M
Valuation & ownership
Enterprise value
$2.8B
Shares out
295.92M
Float
266.33M
Insider %
7.13%
Institutional %
87.13%
Beta
2.13
vs SPY · 52w
Balance sheet & burn
Cash + invest
$295M
Total debt
$113M
Debt / equity
5.13
Cash burn / Q
$36M
R&D spend TTM
$137M
46% of cash
ATM available
None
no active facility
Earnings
EPS latest
$-0.28
EPS Δ vs prior
+0.13
EPS estimate
$-0.15
next quarter
EPS prior
$-0.41
Next earnings
Jun 10, 2026
Rev guidance
$81M